Clinical Trial Detail

NCT ID NCT02158520
Title Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Academic and Community Cancer Research United
Indications

melanoma

Therapies

Ipilimumab

Bevacizumab + Nab-paclitaxel

Age Groups: adult

No variant requirements are available.